Giaccone G, Bagatella M, Donadio M, Bonardi G, Maestroni F, Calciati A
Division of Medical Oncology, Ospedale S. Giovanni, Antica Sede, Torino, Italy.
Tumori. 1989 Feb 28;75(1):43-6. doi: 10.1177/030089168907500112.
No clear evidence of survival benefit has been definitely shown by chemotherapy in advanced non-small-cell lung cancer. We evaluated in a randomized trial the activity of the new drug lonidamine (up to 1050 mg/day) versus MVP (mitomycin C, 10 mg/m2, vinblastine, 5 mg/m2, cisplatin, 100 mg/m2). The preliminary findings on 25 patients showed that lonidamine can be easily administered at these dose ranges, and main toxicity was represented by myalgia and testicular pain. Tolerance to combination chemotherapy (MVP) was superimposable to our prior experience. Responses were recorded in both arms, and no survival difference was apparent. The study is in progress.
化疗在晚期非小细胞肺癌中尚未明确显示出有生存获益的证据。我们在一项随机试验中评估了新药氯尼达明（每日剂量高达1050毫克）与MVP（丝裂霉素C，10毫克/平方米；长春碱，5毫克/平方米；顺铂，100毫克/平方米）的活性。对25例患者的初步研究结果表明，氯尼达明在这些剂量范围内易于给药，主要毒性表现为肌痛和睾丸疼痛。联合化疗（MVP）的耐受性与我们之前的经验相当。两组均有反应记录，且未观察到生存差异。该研究正在进行中。
